Less than a tenth of individuals that would benefit from weight-loss injections including Wegovy can access them, warns the World Health Organization as it releases its inaugural advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for increased and just access to this class of drugs.
Per forecasts, more than two billion could be living with obesity by 2030 unless action is taken.
"Our new guidelines recognises that excess weight is a lifelong illness that can be addressed with thorough and continuous support," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant hurdles to universal availability to the treatments that can assist patients in reducing considerable weight, explains the organization.
Skinny Jab Scarcity
Despite the present best projected scenario, the supply of such drugs could only cover around 100 million people – less than 10% of eligible patients, according to the WHO.
The advice urges nations and manufacturers to increase availability, by strategies including voluntary licensing.
A patent on a key compound – the primary component of Novo Nordisk's Wegovy – is due to expire in several countries in 2026.
The Way Weight-Loss Drugs Operate
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, suppress the appetite and increase satiety so individuals consume fewer calories.
People usually start to lose weight within a few weeks of starting on the once-weekly jabs.
Evidence indicates users may regain a significant portion a year later of stopping the medication, when their typical appetite resume.
To be above a healthy weight elevates your likelihood for developing health problems, like diabetes, cardiovascular issues, stroke, and certain malignancies.
Obesity affects individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, as per the WHO.
